IL13RA2 and BIRC5 Peptide Immunotherapy for Adrenal Cancer Recurrence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for adrenal cancer, including surgical resection and chemotherapy, are inadequate for advanced or metastatic cases, and there is a lack of effective second-line treatments, with high recurrence rates and limited success from cancer immunotherapy.
Innovation Solution
Development of antigen-based immunotherapy targeting interleukin-13 receptor α2 (IL13RA2) and BIRC5 to stimulate an immune response against adrenal cancer, using peptides and nucleic acids to induce a cytotoxic T-lymphocyte response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical resection is performed for adrenal cancer, then the five-year survival rate is 50-60 percent for early-stage tumors, but the prognosis deteriorates to only 10-20 percent five-year survival when tumors have spread to nearby or distant organs
Solution Approach 1:
The patent applies preliminary action by administering immunotherapy treatments before tumors metastasize or progress to advanced stages. The composition stimulates the immune system in advance to recognize and attack cancer cells, preventing the deterioration from 50-60% to 10-20% five-year survival rates associated with metastatic disease
2Adaptability or versatility
If mitotane and cytotoxic chemotherapy are used for locally advanced or metastatic adrenal cancer, then systemic treatment is provided, but no effective second-line therapies are available for patients with disease progression
Solution Approach 1:
The patent applies parameter changes by shifting from conventional cytotoxic chemotherapy to an immunotherapy approach with different mechanisms of action. The composition uses modified peptides with enhanced immunogenicity properties, changing the therapeutic parameters to overcome resistance and provide effective second-line treatment when standard therapies fail
Solution Approach 2:
The patent applies composite materials by combining modified peptides with adjuvants in a single composition. This composite approach integrates multiple therapeutic functions - the modified peptide provides tumor-specific targeting while the adjuvant enhances immune stimulation, creating a more effective treatment than either component alone
3Ease of manufacture
If more than half of patients undergo complete surgical removal of tumors, then initial treatment is achieved, but patients are destined to have relapse often with metastases
Solution Approach 1:
The patent applies continuity of useful action by providing ongoing immune surveillance after surgical resection. The immunotherapy composition maintains continuous immune system activation to detect and eliminate residual cancer cells, preventing relapse and metastasis that would otherwise occur in more than half of surgically treated patients
4Adaptability or versatility
If cancer immunotherapy is applied to adrenal cancer, then treatment is provided, but the success rate is very limited compared to other cancer types
Solution Approach 1:
The patent applies local quality by modifying specific properties of peptides to enhance their immunogenicity for adrenal cancer treatment. The modification pattern creates localized improvements in immune recognition and activation, making the immunotherapy specifically adapted for adrenal cancer rather than using generic immunotherapy approaches
Solution Approach 2:
The patent applies intermediary by using modified peptides as mediators between the immune system and adrenal cancer cells. These peptides serve as the intermediate that bridges immune recognition with tumor-specific targeting, overcoming the limited success of direct immunotherapy approaches in adrenal cancer
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (IL13RA2), BIRC5 and/or FOXM1 for treatment of adrenal cancers. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2, BIRC5 and/or FOXM1 or a sequence variant thereof for treatment of an adrenal cancer. Moreover, the present invention also provides combinations of the (poly)peptide comprising an epitope of IL13RA2, BIRC5 and/or FOXM1 or a sequence variant thereof with (poly)peptides comprising other epitopes or sequence variants thereof for treatment of adrenal cancers.